Long-Term Outcomes after Surgery for Appendiceal Mucinous Tumours

Area of Science:

• Gastroenterology
• Surgical Oncology
• Oncology

Background:

• Appendiceal mucinous tumors (AMT) represent a rare clinical entity.
• Evaluating patient characteristics and long-term outcomes for appendiceal mucinous adenomas and peritoneal pseudomyxoma (PMP) is crucial.

Purpose of the Study:

• To assess preoperative and postoperative factors influencing outcomes in AMT patients.
• To determine the long-term prognosis for patients with appendiceal mucinous adenomas and PMP.

Main Methods:

• A cohort of 25 patients diagnosed with AMT between 2003 and 2013 was analyzed.
• Tumor recurrence and PMP development were diagnosed through clinical evaluation, imaging, and biopsy.
• Survival rates were calculated using the Kaplan-Meier method.

Main Results:

• Histopathology revealed adenoma in 48% of patients, with low-grade PMP in one case (4%).
• Appendiceal mucinous adenocarcinoma (AMCa) was diagnosed in 44% of patients, with PMP in 28% and high-grade AMCa in 8%.
• Five-year survival was 100% for adenomas and 62% for PMP patients; 2 PMP patients did not receive CRS ± HIPEC due to comorbidities.

Conclusions:

• Appendiceal mucinous tumors (AMT) are rare but generally have favorable outcomes, even in advanced stages.
• Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) represent the gold standard for PMP treatment, yielding excellent prognoses.
• While outcomes are promising, further improvements in treatment strategies are anticipated.